AR045930A1 - Compuestos de quinoxalina - Google Patents
Compuestos de quinoxalinaInfo
- Publication number
- AR045930A1 AR045930A1 ARP040102814A ARP040102814A AR045930A1 AR 045930 A1 AR045930 A1 AR 045930A1 AR P040102814 A ARP040102814 A AR P040102814A AR P040102814 A ARP040102814 A AR P040102814A AR 045930 A1 AR045930 A1 AR 045930A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbon
- phenyl
- group
- fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ciertos compuestos amidofenil-sulfonilamino-quinoxalina son moduladores de CCK2 útiles en el tratamiento de enfermedades intermediadas por CCK2. Reivindicación 1: Un compuesto que tiene actividad antagonista de CCK2 de fórmula (1), en la cual: R1 y R2 están cada uno independientemente seleccionados del grupo que consiste en: a) H, alquilo C1-7, alquenilo C2-7, alquinilo C2-7, cicloalquilo C3-7, cicloalquenilo C3-7, cicloalquilo C4-7 benzo-fusionado donde el punto de unión es un átomo de carbono adyacentes a la unión del anillo, cicloalquilo(C3-7)alquilo(C1-7); b) naftil-(CRs2)-, benzoilalquilo(C0-3)-(CRs2)-, fenilo, donde dicho fenilo está opcionalmente fusionado en dos átomos de carbono adyacentes para Rf, fenilo-(CRs2)-, donde dicho fenilo está opcionalmente fusionado en dos átomos de carbono adyacentes con Rf; Rf es una porción hidrocarbonada lineal de 3- a 5- miembros que tiene 0 ó 1 enlace insaturados y que tiene 0, 1 ó 2 miembros de carbono que consisten en un carbonilo; c) Ar6-(CRs2)-, donde Ar6 es un heteroarilo de 6-miembros que tiene carbono como punto de unión, que tiene 1 ó 2 miembros heteroatómicos que son -N= y están opcionalmente benzo fusionados; d) Ar5-(CRs2)-, donde Ar5 es un heteroarilo de 5 miembros que tiene carbono como punto de unión, que tiene 1 miembro heteroatómico seleccionado del grupo que consiste en O, S >NH o >Nalquilo(C1-4), que tiene 0 ó 1 miembro heteroatómico adicional que es -N= y que está opcionalmente benzofusionado; e) Ar6-6-(CRs2)-, donde Ar6-6 es fenilo que tiene el punto de unión y está fusionado a un heteroarilo de 6 miembros que tiene 1 ó 2 miembros heteroatómicos que son -N=; f) Ar5-5-(CRs2)-, donde Ar6-5 es fenilo que tiene el punto de unión y está fusionado con un heteroarilo de 5-miembros que 1 miembro heteroatómico seleccionado del grupo que consiste en O, S >NH o >Nalquil(C1-4) y que tiene 0 ó 1miembro heteroatómico adicional que es -N=; g) alquilo(C1-4)O- y HSalquilo(C1-4); donde R1 y R2 no son simultáneamente H y, excepto en las posiciones en las cuales Rs está indicado, cada uno de a) a g) está situado con 0, 1, 2 ó 3 de Rq; Rq está independientemente seleccionado del grupo que consiste en alquilo C1-4, hidroxi, flúor, cloro, bromo, yodo, trifluormetilo, amino alquilo C1-4, alquilamino(C1-4)alquilo(C1-4), dialquilamino(C1-4)alquilo(C1-4), HO-alquilo(C1-4), alquilo(C1-4)O-alquilo(C1-4), HS-alquilo(C1-4), alquilo(C1-4)S-alquilo(C1-4), alcoxi (C1-4) y alquilo(C1-4)-S-; Rs está independientemente seleccionado del grupo que consiste en H, alquilo C1-4, perhaloalquilo (C1-4), mono- o di- halo alquilo(C1-4), aminoalquilo(C1-4), alquilamino(C1-4)alquilo(C1-4), dialquilamino(C1-4)-alquilo(C1-4), HO-alquilo(C1-4), HS- alquilo(C1-4), alquilo(C1-4)O-alquilo(C1-4), alquilo(C1-4)S-alquilo(C1-4) y fenilo; o, alternativamente, R1 y R2 pueden tomarse conjuntamente con el nitrógeno al cual están unidos y están seleccionados del grupo que consiste en: i) 10-oxa-4-aza- triciclo[5.2.1.02,6]dec-4-ilo, opcionalmente mono- o di-sustituido con Rp; Rp, está independientemente seleccionado del grupo que consiste en hidroxi, alquilo, C1-4, hidroxialquilo C1-4, fenilo, mono-, di- o tri-halo sustituido y hidroxifenilo; ii) un anillo heterocíclico de 4-7 miembros donde dicho anillo heterocíclico tiene 0 ó 1 miembro heteroatómico adicional separado del nitrógeno de unión, mediante por lo menos un miembro de carbono y está seleccionado entre O, S; -N=, >NH o >NRp, que tiene 0, 1 ó 2 enlaces insaturados, que tienen 0, 1 ó 2 miembros de carbono que son un carbonilo, que tiene opcionalmente un miembro de carbono que forma un puente y que tiene 0, 1 ó 2 sustituyentes Rp; iiii) un anillo heterocíclico de 4-7 miembros benzo fusionado donde dicho anillo heterocíclico tiene 0 ó 1 miembros de heteroatómicos adicionales separados del nitrógeno de unión mediante por lo menos un miembro de carbono y están seleccionados entre O, S, -N=, >NH o >NRp, que tiene 0 ó 1 enlace adicional insaturado, que tiene 0, 1 ó miembros de carbono que consisten en carbonilo, que tiene 0, 1, 2 ó 3 sustituyentes halo en el anillo de benceno únicamente y que tiene 0, 1 ó 2 sustituyentes Rp; iv) un anillo heterocíclico de 4-7 miembros donde dicho anillo heterociclilo tiene 0 ó 1 miembros heteroatómico adicional separado del nitrógeno de unión mediante por lo menos un miembro de carbono y que está seleccionado entre O, S, -N=, >NH o >NRp, que tiene 0, 1 ó 2 enlaces insaturados, que tiene 0, 1 ó 2 miembros de carbono que consisten en un carbonilo y que opcionalmente tiene un miembro de carbono que forma un puente, el anillo heterocíclico fusionado en dos átomos de carbono adyacentes forma un enlace saturado o un carbono adyacente y un átomo de nitrógeno que forman un enlace saturado para un anillo hidrocarbonado de 4-7 miembros, que tiene 0 ó 1 miembro heteroatómico posiblemente adicional, no en la unión del anillo, seleccionado entre O, S -N=, >NH o >NRp, que tiene 0, 1 ó 2 enlaces insaturados, que tiene 0, 1 ó 2 miembros de carbono que es un carbonilo y que tiene 0, 1 ó 2 sustituyentes Rp; v) 8-oxo-1,5,6,8-tetrahidro-2H,4H-1,5-metan-pirido[1,2-a][1,5]diazocina-3-ilo, que tiene opcionalmente 0, 1 ó 2 sustituyentes Rp; Ra está independientemente seleccionado del grupo que consiste en alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, fenilo, furanilo, tienilo, bencilo, pirrol-1-ilo, -OH, Oalquilo(C1-6), -Ocicloalquilo(C3-6), -Ofenilo, - Obencilo, -SH, -Salquilo(C1-6), -Scicloalquilo(C3-6), -Sfenilo, -Sbencilo, -CN, -NO2, -N(Ry)Rz (donde Ry y Rz están independientemente seleccionados entre H, alquilo C1-4 o cicloalquilo C1-6 alquilo(C1-4), -(C=O)alquilo(C1-4), SCF3, halo, -CF3, - OCF3, y -COOalquilo(C1-4), o, alternativamente, dos Ra adyacentes, pueden ser tomados conjuntamente con los carbonos de unión para formar un anillo fusionado y están seleccionados del grupo que consiste en fenilo, piridilo y piridinilo; o alternativamente, R2 y uno de Ra pueden tomarse conjuntamente para ser -CH2- o >C=O y para formar un anillo fusionado con el fenilo; Rb está, independientemente, seleccionado del grupo que consiste en alquilo C1-4 y halógeno; y los enantiómeros, diasterómeros, hidratos, y solvatos y sales, ésteres y amidas de los mismos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045930A1 true AR045930A1 (es) | 2005-11-16 |
Family
ID=34193199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102814A AR045930A1 (es) | 2003-08-08 | 2004-08-06 | Compuestos de quinoxalina |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7304051B2 (es) |
| EP (2) | EP1651622B1 (es) |
| JP (2) | JP4818110B2 (es) |
| KR (1) | KR20060060007A (es) |
| CN (2) | CN1863782A (es) |
| AR (1) | AR045930A1 (es) |
| AT (2) | ATE403650T1 (es) |
| AU (2) | AU2004265312B2 (es) |
| BR (1) | BRPI0413449A (es) |
| CA (2) | CA2534885C (es) |
| CR (1) | CR8229A (es) |
| CY (1) | CY1106486T1 (es) |
| DE (2) | DE602004015614D1 (es) |
| DK (2) | DK1651622T3 (es) |
| EA (1) | EA200600203A1 (es) |
| EC (1) | ECSP066355A (es) |
| ES (2) | ES2310294T3 (es) |
| HR (1) | HRP20080559T3 (es) |
| IL (1) | IL173591A0 (es) |
| IS (1) | IS8280A (es) |
| LT (1) | LT5410B (es) |
| LV (1) | LV13453B (es) |
| MX (2) | MXPA06001550A (es) |
| NO (1) | NO20061122L (es) |
| NZ (1) | NZ545030A (es) |
| PL (2) | PL1651621T3 (es) |
| PT (2) | PT1651621E (es) |
| SG (1) | SG131114A1 (es) |
| SI (2) | SI1651622T1 (es) |
| TW (1) | TW200521120A (es) |
| UA (1) | UA84025C2 (es) |
| WO (2) | WO2005016897A1 (es) |
| ZA (1) | ZA200601946B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1651622T3 (da) * | 2003-08-08 | 2007-05-07 | Janssen Pharmaceutica Nv | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser |
| WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| KR20070057252A (ko) | 2004-09-24 | 2007-06-04 | 얀센 파마슈티카 엔.브이. | 설폰아미드 화합물 |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
| WO2008124518A1 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| EP2131245A3 (en) * | 2008-06-02 | 2012-08-01 | ASML Netherlands BV | Lithographic apparatus and its focus determination method |
| US8354557B2 (en) * | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US20100305093A1 (en) * | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| JP5815029B2 (ja) | 2010-07-09 | 2015-11-17 | クオンベルゲンセ プハルマセウトイカルス リミテッド | カルシウムチャネル遮断薬としてのテトラゾール化合物 |
| EP2595988B1 (en) | 2010-07-22 | 2014-12-17 | Zafgen, Inc. | Tricyclic compounds and methds of making and using same |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| JP5941981B2 (ja) | 2011-05-06 | 2016-06-29 | ザフゲン，インコーポレイテッド | 三環式スルホンアミド化合物ならびにその製造および使用方法 |
| WO2012154676A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Partially saturated tricyclic compounds and methods of making and using same |
| EP2705035B1 (en) | 2011-05-06 | 2016-12-14 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| WO2013109739A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| US9440943B2 (en) | 2012-01-18 | 2016-09-13 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| HUE038700T2 (hu) | 2012-03-01 | 2018-11-28 | Allergan Inc | Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| EP2917197B1 (en) | 2012-11-05 | 2019-06-05 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| WO2014071369A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| CN106163527A (zh) | 2013-11-22 | 2016-11-23 | Cl生物科技有限责任公司 | 用于治疗和预防骨质疏松症的胃泌素拮抗剂 |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| PT720601E (pt) | 1993-08-10 | 2001-02-28 | Black James Foundation | Ligandos de receptores de gastrina e cck |
| ATE248823T1 (de) | 1996-12-10 | 2003-09-15 | Zeria Pharm Co Ltd | 1,5-benzodiazepinderivate |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) * | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| DK1651622T3 (da) * | 2003-08-08 | 2007-05-07 | Janssen Pharmaceutica Nv | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser |
| KR20070057252A (ko) * | 2004-09-24 | 2007-06-04 | 얀센 파마슈티카 엔.브이. | 설폰아미드 화합물 |
-
2004
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en active Active
- 2004-08-04 CA CA2534885A patent/CA2534885C/en active Active
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es active Active
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja not_active Expired - Fee Related
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Application Discontinuation
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de active Active
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en active Active
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de active Active
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en active IP Right Grant
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en active IP Right Grant
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es active Active
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 US US10/910,925 patent/US7304051B2/en active Active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en active Active
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en active Active
-
2008
- 2008-11-03 HR HR20080559T patent/HRP20080559T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045930A1 (es) | Compuestos de quinoxalina | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| DK1333833T3 (da) | Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme | |
| AR035763A1 (es) | Compuestos derivados de diamidas heterociclicas, metodo para controlar una plaga de invertebrados y composicion que lo comprende | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| ECSP067098A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20030431A1 (es) | DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7 | |
| WO2007022934A3 (en) | Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors | |
| AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
| PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
| AR060840A1 (es) | Moduladores bencimidazolicos de vr1 | |
| CO5690642A2 (es) | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| CO6260060A2 (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| BRPI0413381A (pt) | composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| PE20030610A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides | |
| AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
| PE20110122A1 (es) | COMPUESTOS DERIVADOS DE 9H-PIRROLO[2,3-b:5,4-c]DIPIRIDIN-6-(PIRIDIN-3-IL) COMO INHIBIDORES DE LAS CINASA Pim | |
| CL2020003227A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. | |
| AR073252A1 (es) | Piridinas fungicidas | |
| CO5700819A2 (es) | Compuestos de benzo[1,2,5]tiadiazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |